Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory IALK/I-Positive Nonsquamous Non-Small-Cell Lung Cancer

Patients with Anaplastic lymphoma kinase (ALK)-positive lung cancer after progression of ALK-tyrosine kinase inhibitor have limited treatment options. This study shows clinical efficacy of the combination of alectinib and bevacizumab with acceptable toxicity in patients with ALK-positive lung cancer...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancers 2022-12, Vol.15 (1)
Hauptverfasser:	Watanabe, Satoshi, Sakai, Kazuko, Matsumoto, Naoya, Koshio, Jun, Ishida, Akira, Abe, Tetsuya, Ishikawa, Daisuke, Tanaka, Tomohiro, Aoki, Ami, Kajiwara, Tomosue, Koyama, Kenichi, Miura, Satoru, Goto, Yuka, Sekiya, Tomoki, Suzuki, Ryo, Kushiro, Kohei, Fujisaki, Toshiya, Yanagimura, Naohiro, Ohtsubo, Aya, Shoji, Satoshi, Nozaki, Koichiro, Saida, Yu, Yoshizawa, Hirohisa, Nishio, Kazuto, Kikuchi, Toshiaki
Format:	Artikel
Sprache:	eng
Schlagworte:	Drug therapy Drug therapy, Combination Lung cancer, Non-small cell Testing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!